Recently approved in Europe and Australia, the multi-component meningococcal B vaccine,
4CMenB (Bexsero®, Novartis Vaccines and Diagnostics), contains three surface-exposed …

Recently approved in the EU, US, Australia, and Canada, 4CMenB (Bexsero®, GSK
Vaccines) is a multi-component meningococcal B (MenB) vaccine containing 3 surface …

Abstract Background 4CMenB (Bexsero), a vaccine developed against invasive
meningococcal disease caused by capsular group B strains (MenB), was recently licensed …

Abstract Background The Meningococcal Antigen Typing System (MATS) was developed to
identify meningococcus group B strains with a high likelihood of being covered by the …

The 4-component meningococcal serogroup B (MenB) vaccine, 4CMenB, the first broadly
protective, protein-based MenB vaccine to be licensed, is now registered in more than 50 …

Introduction: The successful development of two broadly protective vaccines targeting
Neisseria meningitidis serogroup B (MenB); 4CMenB and rLP2086, is the most significant …

A new vaccine, 4CMenB, is composed of surface proteins of Neisseria meningitidis and is
aimed to target serogroup B (MenB) isolates. The vaccine components are present in …

Background In December 2013, a multicomponent meningococcal serogroup B (4CMenB)
vaccine was used before licensure on the basis of special consideration by the Food and …

Summary Background The UK introduced 4CMenB—a multicomponent vaccine against
serogroup B meningococcal disease—into the national infant immunisation programme in …

Background In collaboration with the Canadian Immunization Monitoring Program Active
(IMPACT), the National Microbiology Laboratory, the UK Health Protection Agency and …